In this study, we investigated the in vitro antifungal effects of itraconazole/voriconazole (ITR/VRC) alone and in combination with tetrandrine (TET) against 23 clinical isolates of A. fumigatus using a chequerboard microdilution method. The dynamic antifungal effects of TET with ITR/VRC against A. fumigatus were assessed in vivo using time-kill curves following systemic infection of mice with A. fumigatus. After treatment, efflux pump activity was determined by the efflux of rhodamine 6G (R6G). When ITR was combined with TET, ITR MICs were reduced from 0.125-32 to 0.0625-2 mg ml
INTRODUCTION
Invasive aspergillosis remains an important cause of morbidity and mortality in immunocompromised hosts. Aspergillus fumigatus is the leading cause of invasive aspergillosis worldwide (Tashiro et al., 2012) . Triazoles are first-line antifungals for the treatment of invasive, chronic and allergic diseases caused by Aspergillus spp. (Denning & Hope, 2010) . However, there has been an increasing number of reports describing azole resistance in A. fumigatus (Bueid et al., 2010; Howard et al., 2009; Snelders et al., 2008) , and novel therapeutic approaches are urgently needed to improve outcomes. The introduction of novel antifungals with different mechanisms of action has made combination therapy a possibility and a compelling area of investigation (Steinbach et al., 2003) . Tetrandrine (TET) is a bisbenzylisoquinoline alkaloid extracted from the plant Stephania tetrandra S. Moore. Our previous studies demonstrated that TET acted synergistically with fluconazole against the yeast Candida albicans in vitro and in vivo (Li et al., 2006; Wang et al., 2007) . This synergistic mechanism of action may be related to inhibition of the drug efflux pump and downregulation of the expression of drug Antifungal susceptibility testing. Susceptibility testing was performed according to the broth microdilution chequerboard procedure based on the CLSI M38-A2 standard (Espinel-Ingroff et al., 2010) and previously published protocols (Planche et al., 2012) . Briefly, twofold serial dilutions of drugs were prepared in RPMI 1640 at four times the final desired concentration. Serial dilutions of 50 ml ITR/VRC (final concentration ranging from 0.015 to 16 mg ml 21 ) were added to the wells of 96-well flat-bottomed microtitre plate in columns 2-12, while serial dilutions of 50 ml TET (final concentration ranging from 8 to 512 mg ml 21 ) were added to the wells of rows G-A. Next, 50 ml RPMI 1640 was added to the wells of column 1 and row H, followed by the addition of 100 ml conidial suspension (final concentration 5|10 3 cells ml 21 ) to all wells except well A12, to which 100 ml RPMI 1640 was added. Next, the plates were incubated at 37 uC for 48 h. Visual reading of MICs was performed, and OD 490 was measured by microplate reader. All experiments were performed in triplicate on two separate days.
Drug interaction interpretation. To evaluate the in vitro interactions between ITR/VRC and TET, the data obtained from the chequerboard tests were analysed by non-parametric models based on the Loewe additivity (LA) model and Bliss independence (BI) theory (Odds, 2003; Sun et al., 2008) .
The fractional inhibitory concentration index (FICI) was defined by the equation: SFIC5FIC TET +FIC triazole 5MIC TET+triazole /MIC TET + MIC triazole+TET /MIC triazole , where MIC TET and MIC triazole represent the MICs of TET and ITR/VRC when tested alone, and MIC TET+triazole and MIC triazole+TET represent the MICs of TET in combination with ITR/ VRC. Interactions were categorized according to the previously described method using the following rules: synergism (FICIj0.5), indifference (0.5v FICIj4) and antagonism (FICIw4.0).
The BI-based model was defined as E i 5E A |E B , where E i is the predicted percentage of fungal growth based on a theoretically noninteractive combination of drugs A and B, and E A and E B were the measured percentages of fungal growth with each drug alone. Drug interaction was defined by the difference (DE) between the predicted and measured percentages of growth challenged by drugs at different concentrations (DE5E predicted 2E measured ). When the mean differences of three independent experiments were positive and their 95 % confidence intervals excluded 0, statistically significant synergy was defined; when the mean differences were negative and the 95 % confidence interval excluded 0, statistically significant antagonism was defined. As described previously, statistically significant interactions where DE v100 % were considered weak, while interactions with 100 %vDEj200 % were considered moderate, and interactions with DE w200 % were considered strong.
Time-kill curves. To investigate further the effect of concentration and exposure time on the activity of ITR/VRC alone or in combination with TET, time-kill curves were performed using an adaptation of previously published methods (Bugli et al., 2013; Sun et al., 2009) . Cell viability (i.e. OD) versus time was measured using an XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) assay for the aforementioned fungal biomass-associated metabolic activity (Meletiadis et al., 2001) . Defined concentrations of 1|10 5 cells ml 21 of the azole-sensitive strain AF17 and azole-resistant strain AF23 were added to 96-well microtitre plates and incubated with defined concentrations of each compound (ITR and VRC, 0.5, 1 and 2 mg ml 21 ; TET, 8, 16 and 32 mg ml
21
) at 37 uC. At each time point (0, 1, 2, 4, 8, 12 and 24 h) after incubation, 100 ml XTT/menadione solution was added. The plates were then incubated in the dark for 2 h at 37 uC. Colorimetric changes of the XTT reduction product (formazan) were measured at 490 nm with a microplate reader. All experiments were performed in triplicate on two separate days.
In vivo experiments. Female BALB/c mice (18-22 g; Guangdong Medical Laboratory Animal Center, Foshan, Guangdong, China) were used for all experiments. The mice were housed in filter-top cages with free access to food and water.
Mice were immunosuppressed with cyclophosphamide (200 mg kg 21 ) administered intravenously on day 3 prior to challenge (Denning et al., 1997) . Mice were challenged on day 0 via the lateral vein with conidial suspensions containing 7.5|10 4 cells of the azole-sensitive strain AF17 or 2.5|10 4 cells of the azole-resistant strain AF23. Groups of 10 mice were selected randomly for each strain and treatment.
The in vivo dosing regimens, including dose level, dose interval and treatment duration, were chosen from previous studies (Denning et al., 1997; Dannaoui et al., 2001; Krishnan Natesan et al., 2012; Salas et al., 2013; Warn et al., 2006; Worth et al., 2008 ) intraperitoneally for 7 days. Controls received saline orally or intraperitoneally. For survival studies, mice were checked daily for 22 days after challenge. For tissue burden studies, mice were sacrificed on day 5 p.i., and kidneys and brains (the main target organs) were removed aseptically, weighed and homogenized (Luque et al., 2003) . Serial 10-fold dilutions of the tissue homogenates were plated on PDA, and colonies were counted after 2 days of incubation.
Mortality was compared with Kaplan-Meier survival curves and the log rank test.
Quantitative tissue burdens were compared using the Mann-Whitney test or the Kruskal-Wallis H test in cases where use of the MannWhitney test was not possible.
All animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH publication no. 85-23, revised 1996) . Efflux of rhodamine 6G (R6G). The efflux of R6G was determined using previously published protocols (Brun et al., 2004; Natesan et al., 2013; Shukla et al., 2003) . Briefly, approximately 1|10 8 conidia ml 21 of the azole-sensitive strain AF17 and azole-resistant strain AF23 were incubated in YPD medium at 37 uC for 8 h (early exponential growth phase). Conidia were centrifuged for 5 min, washed with PBS at 4 uC and suspended in glucose-free PBS at a concentration of 1|10 8 cells ml 21 . R6G (10 mM) was added to the conidial suspensions and incubated for 60 min at 37 uC under constant agitation to allow R6G accumulation. The cells equilibrated with R6G were collected by centrifugation, washed with PBS and resuspended at a 2 % concentration in glucose-free PBS. At 0, 5, 10, 15, 20, 25, 30, 35, 40 and 45 min time points, samples of 1 ml were withdrawn and centrifuged for 2 min. The supernatants were collected and transferred into 96-well microtitre plates, and the absorbance of supernatants was measured at 527 nm. Energydependent efflux at the indicated times was measured after glucose was added to the supernatants in glucose-free PBS. For competition studies, TET (256 mg ml 21 ) was added to the de-energized cells 5 min prior to the addition of R6G. Glucose-free controls were used in all the experiments.
At the 35 min time point, samples of 1 ml were withdrawn, centrifuged, washed and resuspended in glucose-free PBS. The fluorescence of the cells was quantified immediately at 533 nm with a flow cytometer (FACS Aria, BD). R6G-free controls were included in all experiments.
RESULTS

Antifungal susceptibility testing
The MICs of ITR/VRC alone and in combination with TET against A. fumigatus are shown in Table 1 . The MICs of ITR and VRC alone against the quality-control strain C. parapsilosis ATCC 22019 were 0.125-0.25 and 0.0625-0.125 mg ml 21 , respectively, which were within the reference range described by CLSI M38-A2 (Espinel-Ingroff et al., 2010) . Based on a 90 % reduction in growth when TET was administered in combination with ITR, the MICs of TET were reduced from 256-512 to 8-64 mg ml 21 , and the MICs of ITR were reduced from 0.125-32 to 0.0625-2 mg ml
21
. When TET was administered in combination with VRC, the MICs of TET were reduced from 256-512 to 8-256 mg ml 21 , and the MICs of VRC were reduced from 0.125-2 to 0.03125-0.5 mg ml 21 . The results of the drug interaction study interpreted by the FICI and DE models are summarized in ITR25+TET60  ITR25+TET40  ITR25+TET20  ITR25  TET60  TET40  TET20  Control   ITR75+TET60  ITR75+TET40  ITR75+TET20  ITR75  TET60  TET40  TET20  Control   ITR75+TET60  ITR75+TET40  ITR75+TET20  ITR75  TET60  TET40 ) reduced the percentage cell viability from 51.1 % at 8 h to 20.2 % at 24 h for the azole-sensitive strain AF17 and from 35.8 % at 8 h to 37.2 % at 24 h for the azole-resistant strain AF23 (Fig. 1a, b) . Moreover, treatment with TET (32 mg ml 21 ) in combination with ITR (2 mg ml
) reduced the percentage cell viability from 21.8 % at 8 h to 0.97 % at 24 h for the azole-sensitive strain AF17 and from 50.3 % at 8 h to 15.7 % at 24 h for the azole-resistant strain AF23 compared with ITR alone (Fig. 1e, f) . Similar results were obtained with TET in combination with VRC (Fig. 2) .
Overall, the results showed that TET strikingly enhanced the antifungal effects of ITR/VRC against A. fumigatus, resulting in reduced cell viability over a shorter time period.
In vivo experiments
The survival curves (Figs 3 and 4) demonstrated that both the azole-sensitive strain AF17 and azole-resistant strain AF23 caused acute and lethal infections in mice. Treatment with TET alone resulted in 20 and 10 % survival, respectively, which did not significantly prolong survival compared with the control mice (Pw0.05). Treatment with a low dose of ITR (25 mg Thus, TET acted synergistically with ITR/VRC against A. fumigatus in vivo.
Efflux of R6G
To evaluate the drug efflux capacity of A. fumigatus and the ability of TET to mediate efflux reversal, we measured extracellular R6G concentrations in both azole-sensitive and azole-resistant strains in the absence or presence of TET using spectrophotometry analysis. As shown in Fig. 7 , there was a sharp increase in measured extracellular R6G concentrations when glucose was added to the conidial suspensions. However, no R6G efflux occurred when both strains were maintained for another 35 min in the absence of glucose, suggesting that the energy-dependent efflux pump activity is enhanced in the presence of glucose. The efflux effect was more pronounced in the azole-resistant strain AF23 compared with the azolesensitive strain AF17. There was no increase in measured extracellular R6G concentrations when TET was added to the conidial suspensions. Furthermore, there was a decrease in measured extracellular R6G concentrations following the addition of glucose and TET compared with conidial suspensions provided only glucose.
We also measured intracellular R6G fluorescence intensity using flow cytometry. As shown in Fig. 8 , the mean fluorescence intensity of the cells of both strains was lower after 30 min incubation in PBS with glucose (Fig. 8 , curve C) than in PBS without glucose (Fig. 8, curve B) . In contrast, the mean fluorescence intensity of cells of both strains was higher after 30 min incubation in PBS with glucose and TET (Fig. 8 , curve D) than in PBS with glucose alone (Fig. 8, curve C) .
Taken together, our results suggest that TET inhibits the drug efflux of A. fumigatus.
DISCUSSION
ITR and VRC are first-line antifungals used for the treatment of invasive aspergillosis (Denning & Hope, 2010) . However, there have been increasing reports of azole resistance in A. fumigatus (Bueid et al., 2010; Howard et al., 2009; Snelders et al., 2008) , resulting in treatment failure in approximately 50 % of patients (Cornely et al., 2011) . Novel antifungals with different mechanisms of action have made combination therapy a possibility (Steinbach et al., 2003) . Our previous studies demonstrated that TET acts synergistically with fluconazole against the representative yeast C. albicans both in vitro and in vivo (Li et al., 2006; Wang et al., 2007) . Mechanistically, this appeared to be related to inhibition of the drug efflux pump via downregulation of its associated genes ). The present study investigated this synergistic effect and determined the antifungal mechanism of TET and ITR/VRC against clinical isolates of the representative deep filamentous fungus A. fumigatus.
The MICs of ITR in combination with TET were decreased two-to fourfold and three-to sixfold across a series of concentration gradients in vitro compared with ITR and TET ).
S.-X. Li and others alone, respectively. Similarly, the MICs of VRC in combination with TET decreased one-to fourfold and one-to sixfold across a series of concentration gradients versus VRC and TET alone, respectively. Time-kill curves further revealed that the synergy was dependent on ITR/VRC and TET concentrations and incubation time. Furthermore, ITR/VRC in combination with TET significantly prolonged survival time and reduced kidney and brain tissue burdens in vivo versus ITR/VRC alone. Taken together, these data demonstrated that TET acts synergistically with ITR/VRC against A. fumigatus.
The azole resistance mechanisms of A. fumigatus are mediated mainly by gene cyp51A mutation (Howard et al., 2009; Mellado et al., 2007; Snelders et al., 2008 Snelders et al., , 2010 and overexpression of the drug efflux pump and its associated genes (da Silva Ferreira et al., 2004; Nascimento et al., 2003; Slaven et al., 2002; Tobin et al., 1997) . Our previous studies demonstrated that none of the azole-resistant isolates of this study carried the cyp51A mutation. However, the R6G efflux results showed that the drug efflux pump results in the ITR-resistant strain AF23 were higher than in the ITR-sensitive strain AF17. Therefore, the results indicated that the resistance mechanisms of the azole-resistant isolates of this study are responsible for overexpression of the drug efflux pump. Furthermore, analysis of R6G efflux revealed that TET could inhibit the drug efflux pump of A. fumigatus. Zhang et al. (2009) also demonstrated that the synergistic mechanism of TET with fluconazole against C. albicans was related to inhibition of the drug efflux pump and downregulation of drug efflux pump genes. Guo et al. (2014) found that the synergistic mechanism of TET to fluconazole against C. albicans was related to the generation and transport of ATP, resulting in reduced utilization of ATP and inhibition of drug efflux pump activity. These findings suggest that the synergistic mechanism of TET with ITR/ VRC against A. fumigatus may be related to inhibition of the drug efflux pump. However, further studies including gene cloning, knockout and transformation experiments are needed to focus on analysing the functional link between the efflux pump genes and the resistant mechanism of A. fumigatus, and the synergistic mechanism of TET.
TET, a Chinese herb extract, has low cytotoxicity, is abundant, has minimal side effects and is synergistic with antifungal drugs. We found that a therapeutic dose of TET alone had no intrinsic antifungal activity but could improve the antifungal activity of azole when administered in combination in vitro and in a mouse model in vivo.
Because it is safe and effective and its primary mechanism has been clearly defined in this and previous studies, TET is a potential synergist of antifungal drugs with clinical value.
